Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $6.5 million.

  • Ptc Therapeutics' Change in Receivables fell 1612.9% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 12736.55%. This contributed to the annual value of -$1.7 million for FY2024, which is 21254.06% down from last year.
  • Ptc Therapeutics' Change in Receivables amounted to $6.5 million in Q3 2025, which was down 1612.9% from -$21.9 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Change in Receivables peaked at $47.8 million during Q1 2025, and registered a low of -$40.8 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Receivables was $6.5 million (2025), whereas its average is $6.6 million.
  • Examining YoY changes over the last 5 years, Ptc Therapeutics' Change in Receivables showed a top increase of 116606.99% in 2021 and a maximum decrease of 330781.89% in 2021.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Change in Receivables stood at $16.4 million in 2021, then surged by 44.78% to $23.7 million in 2022, then plummeted by 135.23% to -$8.3 million in 2023, then plummeted by 388.27% to -$40.8 million in 2024, then skyrocketed by 115.88% to $6.5 million in 2025.
  • Its Change in Receivables was $6.5 million in Q3 2025, compared to -$21.9 million in Q2 2025 and $47.8 million in Q1 2025.